Moderna Inc. shares jumped 6.5% in after-hours trade following the publication of FDA staff briefing documents that presented a largely positive appraisal of the company’s mFlusiva mRNA seasonal influenza vaccine. The documents set expectations ahead of an advisory committee meeting scheduled for June 18 that will review the vaccine.
FDA reviewers reported that trial data showing a robust immune response to the candidate could support its effectiveness in adults aged 65 and older. In addition, the vaccine demonstrated superior relative efficacy compared with a standard-dose influenza shot in adults 50 to 64 years old. That combination of findings materially reduced regulatory uncertainty around the upcoming panel vote.
The current regulatory readout follows a rocky exchange earlier this year. In February, the FDA issued a refusal-to-file letter for the same application, citing an inadequate comparator arm in the trial. The agency subsequently reversed course and agreed to evaluate the submission through a modified age-stratified approval pathway. The staff briefing released Tuesday presented a more constructive tone, easing concerns that the agency might again raise significant efficacy objections.
Concurrently, Moderna disclosed an internal leadership reorganization. The company expanded President Stephen Hoge’s cross-functional responsibilities and appointed Ester Banque as Chief Commercial Officer. Market observers treated those personnel moves as preparatory steps for potential commercialization, with company statements noting readiness for up to three possible product launches in 2027 and 2028.
The price reaction was company-specific. Broader markets did not provide support for the rally: the NASDAQ fell during the trading session and the S&P 500 also closed lower. Peers in the vaccine sector did not experience comparable gains, indicating the mFlusiva regulatory development and corporate adjustments were the principal drivers of Moderna’s share move.
Taken together, the FDA staff’s favorable interpretation of efficacy data, the impending advisory committee vote, and the executive changes signaling commercial preparedness combined to lift Moderna stock sharply. The share price moved toward the company’s 52-week high of $59.55, representing a significant rebound from the $22.28 low recorded over the past year.
Summary
FDA staff briefing documents for Moderna’s mFlusiva vaccine suggested immune responses and relative efficacy that could support approval in older adults and reduce regulatory risk ahead of a June 18 advisory committee review. The company also reorganized its leadership to broaden commercial oversight and added a chief commercial officer, moves viewed as preparing for potential product launches in 2027 and 2028. The announcements drove a company-specific after-hours rally while broader indices declined.
Key points
- FDA staff concluded data may support mFlusiva effectiveness in adults 65 and older and showed superior relative efficacy in ages 50-64 compared with a standard-dose shot.
- Moderna expanded President Stephen Hoge’s cross-functional oversight and named Ester Banque Chief Commercial Officer as it prepares for potential product launches in 2027 and 2028.
- The stock’s after-hours rise was isolated to Moderna, with the NASDAQ and S&P 500 both finishing the day lower and vaccine peers not matching the gain.
Risks and uncertainties
- The advisory committee vote on June 18 remains a critical upcoming event and its outcome is uncertain despite the FDA staff briefing.
- Past regulatory friction - including the February refusal-to-file due to an inadequate comparator arm - highlights ongoing regulatory scrutiny of the mFlusiva data and processes.
- The market reaction was company-specific; broader market weakness and the lack of similar moves among vaccine peers indicate that sector-wide support for the rally is not established.